Mylan and Pfizer delay Upjohn merger amid coronavirus pandemic

27 March 2020 (Last Updated March 27th, 2020 11:40)

Mylan’s merger with Pfizer’s off-patent branded drugs unit Upjohn is now expected to close in the second half of this year due to the coronavirus pandemic.

As a result of restrictions on large gatherings in the Netherlands, Mylan’s extraordinary general meeting of shareholders to approve certain matters for the transaction has been postponed from 27 April to 30 June.

There were no other amendments to previously announced terms or plans related to the merger.

Read the full article here